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a b s t r a c t
The antidepressant agomelatine is a MT1/MT2 receptor agonist and 5-HT2C antagonist. Its antidepressant
activity is proposed to result from the synergy between these sets of receptors. Agomelatine-induced
changes in the brain have been reported under basal conditions. Yet, little is known about its effects in
the brain exposed to chronic stress as a risk factor for major depressive disorder. Recently, we described
agomelatine-induced changes on neuronal activity and adult neurogenesis in the hippocampus of rats
subjected to chronic footshock stress. In order to better characterize the actions of agomelatine in the
stress-compromised brain, here we investigated its effects on hippocampal neurogenesis in the chronic
mild stress (CMS)model. Adultmale ratswere subjected to variousmild stressors for 5weeks, and treated
with agomelatine during the last 3 weeks of the stress period. The sucrose preference test was performed
weekly to measure anhedonia, and the marble burying test was carried out at the end of the experimentepression
i-67
to assess anxiety-like behavior. In ourmodel, the CMS paradigmdid not change sucrose preference; how-
ever, it increased marble burying behavior, indicating enhanced anxiety. Interestingly, this stress model
differentially affected distinct stages of the neurogenesis process.Whereas CMSdid not inﬂuence the rate
of hippocampal cell proliferation, it signiﬁcantly decreased the newborn cell survival and doublecortin
expression in the dentate gyrus. Importantly, treatment with agomelatine completely normalized stress-
affected cell survival and partly reversed reduced doublecortin expression. Taken together, these data
as benshow that agomelatine h. Introduction
Depression is a devastating illness and a major contribu-
or to the global disease burden [1,2]. Treatment of depressive
Abbreviations: 5-HT, serotonin; Ago, agomelatine; Akt, protein kinase B; BrdU,
romodeoxyuridine; BDNF, brain-derived neurotrophic factor; CMS, chronic mild
tress; CREB, cyclic adenosinemonophosphate responsive element binding protein;
TR, control group;DCX,doublecortin; ERK1/2, extracellular signal-regulatedkinase
/2; GCL, granular cell layer; GR, glucocorticoid receptor; GSK3, glycogen synthase
inase 3; HEC, hydroxyethylcellulose; ir, immunoreactivity; MR, mineralocorti-
oid receptor; MT, melatonin receptor; NRI, noradrenaline reuptake inhibitor; OD,
ptical density; SGZ, subgranular zone; SNRI, serotonin and noradrenaline reuptake
nhibitor; SP, sucrose preference; SPT, sucrose preference test; SSRI, selective sero-
onin reuptake inhibitor; STR, stressed group; VEGF, vascular endothelial growth
actor; Veh, vehicle.
∗ Corresponding author at: Department of Molecular Neurobiology, University of
roningen, P.O. Box 14, 9750 AA Haren, The Netherlands. Tel.: +31 50 363 2339;
ax: +31 50 363 2331.
E-mail address: G.Dagyte@rug.nl (G. Dagyte˙).
166-4328/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
oi:10.1016/j.bbr.2010.11.045eﬁcial effects on hippocampal neurogenesis in the CMS paradigm.
© 2010 Elsevier B.V. All rights reserved.
disorder remains a challenge, despite of several classes of
antidepressant drugs available. Currently, most of depressed
patients are treated with monoaminergic compounds, such as
selective serotonin reuptake inhibitors (SSRI), serotonin and nora-
drenaline reuptake inhibitors (SNRI), and noradrenaline reuptake
inhibitors (NRI), which potentiate the brain’s monoaminergic
system and elevate the monoamine levels [3]. However, only
about 50% of the depressed patients treated with these medi-
cations achieve complete remission [4,5]. Moreover, rather poor
tolerability of currently used antidepressants and late onset of
their therapeutic effects further increase the risk of unsuccessful
treatment [6]. Thus, there is a need for novel and more efﬁ-
cient medications with fundamentally different mechanism of
action.Search for new targets in treatment of depression has led to
the development of the ﬁrst melatonergic antidepressant, agome-
latine [7]. This novel drug acts as a potent agonist of melatonergic
(MT1/MT2) receptors as well as an antagonist of the serotonergic
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atine have been demonstrated in both animal models [10–12] and
n clinical studies [13–16]. The antidepressant efﬁcacy of agomela-
ine includes beneﬁcial effect on sleep quality, achieved via synergy
etween the melatonergic and 5-HT2C receptors [17]. Current lit-
rature indicates that the therapeutic actions of agomelatine are
ediated through different mechanisms as compared to SSRI and
ricyclics [18,19]. Nevertheless, molecular correlates underlying
he antidepressant action of agomelatine merit further investiga-
ion.
In an attempt to unravel the working mechanism of agomela-
ine, preclinical studies reported a variety of its mediated changes
n the brain. In experiments with unchallenged laboratory animals,
gomelatine was shown to enhance adult hippocampal neurogen-
sis, to increase expression of brain-derived neurotrophic factor
BDNF), and to activate several cellular signals, i.e. extracellular
ignal-regulated kinase 1/2 (ERK1/2), protein kinase B (Akt), and
lycogen synthase kinase 3 (GSK3) [20–22]. This information
onsiderably advanced understanding of agomelatine’s action in
he brain. However, since effects of antidepressant drugs might
iffer in disturbed versus intact systems [6], the latter ﬁndings
nder basal conditions are not possible to directly extrapolate to
he therapeutic action of agomelatine in depression. This gap may
epartially bridgedbyapplyingananimalmodel approach, inorder
o elucidate effects of agomelatine under conditions that might
redispose to mood disorders.
Animal models of chronic stress represent a valuable tool
o investigate behavioral, endocrine and neurobiological changes
nderlying stress-related psychopathologies, such as major
epression, and efﬁcacy of antidepressant therapies [23,24]. The
hronic mild stress (CMS) paradigm has been proposed as an ani-
al model of depression [25]. In laboratory animals, this chronic
tress procedure attempts to mimic some of the dysfunctions
ssociated with human depressive disorder. As such, CMS was
eported to induce anhedonia, which could be reversed by antide-
ressant treatment [10,26,27]. Also, CMS was demonstrated to
educe expression of BDNF and activation of cyclic adenosine
onophosphate responsive element binding protein (CREB), both
mplicated in pathophysiology of depression and working mech-
nism of antidepressants [28–30]. Moreover, CMS was shown to
uppress adult hippocampal neurogenesis, suggested to play a
ole in depressive disorder and action of antidepressant drugs
31–33]. Although impairments in hippocampal neurogenesis have
ot yet provided functional mechanism for the pathophysiology
f depression, this phenomenon gained an enormous interest
mong researchers [34]. In particular, the notion that hippocampal
eurogenesis may be oppositely regulated by stress and antide-
ressants gave rise to the possibility of using it as a read-out in
esting the efﬁcacy of novel treatments for major depressive disor-
er.
Altogether, this encouraged us to apply agomelatine treatment
n chronically stressed animals, in order to explore its therapeutic
ctions and mechanisms behind them. Recently, we character-
zed agomelatine-induced changes in the brain of rats exposed to
hronic footshock stress. In this model, treatment with agomela-
ine normalized stress-affected neuronal activity and promoted
eurogenesis in the hippocampus [35]. In order to better char-
cterize the action of agomelatine in the stress-compromised
rain, here we investigated its effects on hippocampal neu-
ogenesis in the CMS model. We asked whether this stress
aradigm induced differential changes in distinct stages of the
eurogenesis process (cell proliferation, survival and neuronal
ifferentiation), and whether agomelatine treatment reversed
hem. In addition, we assessed effects of CMS and agomela-
ine on anhedonia and anxiety-like behavior by using sucrose
reference and marble burying tests as respective behavioral
aradigms.esearch 218 (2011) 121–128
2. Experimental procedures
2.1. Animals and housing
The experiments were performed using adult male Wistar rats (Harlan, Horst,
The Netherlands) weighing 250–300g at the beginning of the experiment. The
animals were housed individually in a climate-controlled room with constant tem-
perature (21±1 ◦C) and a 12h light/12h dark cycle (lights on at 05:00h). Food
and water was available ad libitum, except when food deprivation was applied as
a stressor. The experiments were approved by the ethical committee for the use
of experimental animals of the University of Groningen and carried out in accor-
dance with the European Communities Council Directive of 24 November 1986
(86/609/EEC).
2.2. Experimental protocol
During a 2-week acclimatization period before the start of the experiment, all
rats were handled, weighed and trained to consume 1% sucrose solution. Three
habituation tests for sucrosewere performed, followed by a baseline sucrose prefer-
ence test (SPT). On the basis of their sucrose preference in the baseline SPT, animals
were divided into two matched groups, home-cage control and chronic stress. Both
groups were further subdivided into three subgroups, based on the drug treat-
ment (untreated, treated with vehicle or agomelatine). Thus, six groups of rats were
used for the present experiment: three groups of control rats, which were either
untreated (CTR) or treated with vehicle (CTR-Veh) or agomelatine (CTR-Ago), and
three groups of chronically stressed rats, which were also either untreated (STR) or
treated with vehicle (STR-Veh) or agomelatine (STR-Ago). Each group consisted of
7–8 animals. Stress group rats were exposed to a 5-week CMS procedure, whereas
control rats stayed undisturbed in a separate room. Drug treatment started on the
third week of the experiment, and continued daily throughout the ﬁnal 3 weeks of
the 5-week experimental period. At the end of every week, the SPT was applied to
all rats. In the last week of the experiment, the marble burying test was performed.
At the end of the 5-week experiment, the home-cage control rats were sacriﬁced
concomitantly with the stressed rats which were euthanized 4–6h after the last
stressor exposure and 18–20h after the last treatment administration.
2.3. Chronic mild stress procedure
The CMS protocol was adapted from previous studies [10,36]. In the current
experiment, the CMS procedure consisted of ﬁve different mild stressors, applied
randomly every week for 5 weeks. These ﬁve stressors were: 16h of food depri-
vation, 16h of soiled cage (500ml water in 250g sawdust bedding), 16h of tilted
cage (45◦), 12h of predator sounds (high-pitch medium volume, resembling snake
sounds) and 12h of medium intensity of stroboscopic light ﬂashes. These stressors
were applied during the entire dark phase and ﬁrst 4h of the light phase, in case of
the stressors with 16h duration. Every experimental week consisted of 5 days with
random stressors, and 2 days of no-stress.
2.4. Sucrose preference test
The sucrose preference test (SPT) was conducted as a measure for the anhedo-
nic effect of CMS [36]. A two bottle preference test was used, where all animals got
access to both water and a 1% sucrose solution for 24h during a period of no-stress.
In order to habituate animals to the sucrose solution, they were trained during the
acclimatization period. Three habituation tests were performed, where animals had
access to both water and sucrose solution for 24h. This training period was fol-
lowed by the baseline SPT, 1 day before the start of the CMS protocol. During the
5-week CMS procedure, SPT was performed at the end of each experimental week
for 24h during a period of no-stress. Bottles with water and sucrose solution were
switched regularly to control for the place preference. The ﬁnal SPT was performed
24h before the last treatment administration. Sucrose preference (SP) was calcu-
lated as the percentage of sucrose solution ingested relative to the total amount of
liquid consumed (SP= [sucrose solution, g/sucrose solution, g +water, g]×100).
2.5. Marble burying test
The marble burying test was used to measure an anxiety-induced behavioral
response to environmental challenge. Itwasperformed in the lastweekof the exper-
iment, during the light phase of a stress-free period. The method was adapted from
previous studies [37,38]. Brieﬂy, four glassmarbles (2.5 cm in diameter)were placed
along a side-wall of each home-cage, and behavior of rats was observed during a
30-min test period. The following parameters were recorded: the number of rats
showing burying behavior, and the number of buried marbles (at least two thirds
of the surface covered with sawdust). Marble burying behavior reﬂected an active
effort of a rat to hide the unfamiliar object in sawdust bedding, and therefore, it may
indicate anxiety-like behavior [38].
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.6. Drug treatment
1% hydroxyethylcellulose (HEC) was used as a vehicle for agomelatine delivery.
gomelatine solution was prepared every day by dissolving agomelatine powder in
%HEC at a concentration of 40mg/ml. The choice of agomelatine dosewasmade on
he basis of its activity at this concentration in animalmodels of depression and anx-
ety [10,39], and on neuroplasticity [20,21,35]. Rats were injected intraperitoneally
ither with agomelatine (40mg/kg) or vehicle daily at 15:00 (2h prior to the dark
hase) for 21 days. Injections started on the third week of the 5-week experimental
eriod. Agomelatine and HEC were provided by Servier (France).
.7. BrdU labeling
In order to study survival of newly-born cells in the hippocampus during the
xperiment, rats receivedan injectionof bromodeoxyuridine (BrdU: Sigma, St. Louis,
O, USA), a synthetic analogue of thymidine which is incorporated into newly syn-
hesized DNA of replicating cells during the S phase of the cell cycle [40]. New cells
ere labeled 4 days before the start of the experiment with a single intraperitoneal
njection (300mg/kg). This speciﬁc time-point of BrdU labeling for studying cell sur-
ival was chosen since it was shown that labeled progenitor cells stop proliferating
fter 4 days [41]. Such an injection schedule was similarly applied in our laboratory
reviously [35,42,43].
.8. Brain collection and immunohistochemistry
At the end of the experiment rats were anesthetized with sodium pentobarbital
nd transcardially perfused with heparinized saline followed by 4% paraformalde-
yde solution in 0.1M phosphate buffer. Brains were extracted and post-ﬁxed in
he same solution overnight at 4 ◦C and subsequently cryoprotected by immersion
n a 30% buffered sucrose solution for up to 48h. Coronal serial sections of 30m
ere cut using a cryostat and stored in 0.01M phosphate-buffered saline with 0.1%
odium azide at 4 ◦C until immunohistochemistry was performed.
In order to assess effects of CMS and agomelatine on different aspects of hip-
ocampal neurogenesis, immunohistochemistry for Ki-67, doublecortin (DCX), and
rdU was performed. Ki-67 is a nuclear protein which is expressed during all phases
f the cell cycle, except G0 [44], which would therefore give an indication of cell
roliferation on the last day of the experiment. DCX protein is expressed in newly-
orn cells from 1 day to about 4 weeks of age, and might therefore reveal sustained
hanges in the neurogenesis process and its modulation [45,46]. Finally, since a pool
f newborn cells was labeled with an injection of BrdU 4 days prior to the start of
he experiment, BrdU immunostaining would indicate changes in survival of new
ells in the course of the experiment.
The immunostainings were performed on free-ﬂoating sections under contin-
ous mild agitation. BrdU immunohistochemistry required extra steps for DNA
enaturation. For this purpose, sections were exposed to 2× saline sodium citrate
2×SSC) containing 50% formamide for 30min at 65 ◦C, followed by a rinse with
×SSC, incubation with 2M HCl for 30min at 37 ◦C and a washing step with 0.1M
orate buffer. Brain sections for all three immunostainings were preincubated in 3%
ormal serum and 0.1% TritonX-100, and then incubated with one of the follow-
ng antibodies for 60h at 4 ◦C: primary mouse-anti-Ki-67 (1:200; Monosan, Uden,
heNetherlands), goat-anti-DCX (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA,
SA), or rat-anti-BrdU (1:800; Serotec, Oxford, UK). Subsequently, sections were
insed in 0.01M Tris-buffered saline and incubated for 2h at room temperature
ith secondary biotinylated goat-anti-mouse, rabbit-anti-goat or donkey-anti-rat
ntibody depending on the primary antibody host (1:500 for all secondary anti-
odies, Jackson ImmunoResearch Suffolk, UK). Then, avidin–biotin complex (1:500,
ector ABC kit, Vector Laboratories, Burlingame, CA, USA) was added for 2h, after
hich the stainingwas visualizedwith1mg/mldiaminobenzidine and0.003%H2O2.
hereafter, sections were rinsed, mounted on slides, dehydrated and coverslipped
or microscopic analysis.
.9. Quantiﬁcation
All analyseswereperformedbyanobserver blind to thegroupassignment. Ki-67
ndBrdUpositive cellswere counted in the subgranular zone (SGZ) and granular cell
ayer (GCL) of the dentate gyrus in every twelfth section of the hippocampus under
00×magniﬁcation. Immunopositive cells thatwere located one cell diameter away
rom SGZ were also included in the analysis. The number of immunopositive cells
n each section was expressed relative to the length of the dentate gyrus in order
o correct for variation in size of the hippocampus along the rostro-caudal axis of
he brain. The length of the dentate gyrus was measured by delineating the entire
GZ in each hippocampus. DCX immunoreactivity (ir) in cell bodies and dendrites of
he newly generated cells was measured by a previously described method [43,47].
easurementswereperformedwith a computerized system(Leica, Cambridge,UK).mages were taken using a Leica charged-coupled device digital camera mounted
n a microscope (DMIRB, Leica, Cambridge, UK) at 100× magniﬁcation. In total, 7–8
ections per animal (Bregma −2.56 to −6.30, according to the rat brain atlas [48]
ere analyzed by delineating a similarly sized area covering the entire width of
he SGZ and GCL in each hippocampus. Optical density (OD) of DCX expression was
easured in the dentate gyrus and corrected for non-speciﬁc background labeling,Fig. 1. Changes in body weight gain throughout the experiment. Both CMS and
agomelatine treatment signiﬁcantly reduced body weight gain. Arrows point at
short-term body weight decreases due to the food deprivation stressor.
whichwasmeasured in the corpus callosum.TheODwasexpressed inarbitraryunits
corresponding to grey levels using a Quantimet 550 image analysis system (Leica,
Cambridge, UK). Simultaneously, a secondmeasure of theDCX immunostainingwas
taken, complementary to theDCXODanalysis.Within eachdelineated area covering
the SGZ and GCL, the percentage of the total surface that was covered with DCX-
positive cell bodies and dendrites was calculated, and presented as area coverage
(%). In all three stainings, dorsal and ventral hippocampi were analyzed separately.
Since similar changes in the dorsal and ventral parts of hippocampus were detected,
these data were pooled and effects in the entire hippocampus were presented.
2.10. Statistics
Two-wayANOVAwasused to analyze the effects of stress anddrug treatment on
hippocampal neurogenesis and marble burying. The body weight gain and sucrose
preference data were analyzed by repeated measures ANOVA. When signiﬁcant
effects were found, post-hoc analysis was performed using the Fisher LSD test. The
level of signiﬁcance was set at p<0.05.
3. Results
3.1. Body weight gain
Body weight was measured from day −7 to day 35 of the
experiment. All rats grew at similar rates during the acclimati-
zation period. However, CMS and agomelatine treatment signif-
icantly reduced body weight gain (repeated measures ANOVA,
time× stress interaction: F(30,1230) = 32.85, p<0.001; time×drug
interaction: F(60,1230) = 15.79, p<0.001; Fig. 1).
3.2. Sucrose preference test
Preference for 1% sucrose solution over water was measured
before the start of the CMS procedure (baseline) and weekly during
the 5-week experimental period. Repeated measures ANOVA did
not reveal any signiﬁcant differences in sucrose preference among
the groups throughout the experiment (p>0.05; Fig. 2).
3.3. Marble burying test
The number of buried marbles by each animal was recorded
during a 30-min test period. Fig. 3A depicts the average number
of buried marbles in each experimental group. Individual variation
associatedwith this behavioralmeasure is illustrated in Fig. 3B. The
data points correspond to individual animals, and show the num-
ber of their buried marbles. Two-way ANOVA revealed a signiﬁcant
stress-induced increase in burying behavior (F(1,41) = 5.18, p=0.03,
when the number of animals showing burying behavior was ana-
124 G. Dagyte˙ et al. / Behavioural Brain R
Fig. 2. Effects of CMS and agomelatine treatment on sucrose preference. A prefer-
ence for 1% sucrose solution over water was measured before the start of the CMS
procedure (baseline) and weekly during the 5-week experimental period. CMS did
not induce signiﬁcant changes in sucrose preference among the groups throughout
the experiment.
Fig. 3. Effects of CMS and agomelatine treatment on marble burying. The graph
depicts the average number of buried marbles in each experimental group (A). This
measurewas associatedwith a high individual variation, andnot all animals showed
burying behavior (B). The data points correspond to individual rats, and reveal the
number of their buried marbles. Some data points represent more than one animal;
their n is indicated below each point. CMS induced a signiﬁcant increase in burying
behavior (both in the number of rats showing burying behavior and in the number
of their buried marbles). Although agomelatine treatment seemed to reduce bury-
ing behavior, its effects did not reach statistical signiﬁcance. p<0.05 (overall stress
effect).esearch 218 (2011) 121–128
lyzed; F(1,41) = 5.06, p=0.03, when the number of buried marbles
across the groups was compared). Agomelatine treatment reduced
burying behavior (only 29% of stressed agomelatine-treated rats
buried marbles as compared to 63% of stressed non-injected and
50% of stressed vehicle-treated animals), but this effect did not
reach statistical signiﬁcance.
3.4. Hippocampal neurogenesis
Fig. 4 shows representative examples of Ki-67 (A), BrdU (B)
and DCX (C) immunostainings in the hippocampal dentate gyrus.
Changes in different stages of hippocampal neurogenesis after CMS
and agomelatine treatment are depicted in Fig. 5.
Hippocampal cell proliferation was assessed by Ki-67 immuno-
histochemistry (Fig. 4A). There were no signiﬁcant differences
in the number of proliferating cells among the groups (p>0.05;
Fig. 5A).
Hippocampal cell survival was assessed by BrdU immunohis-
tochemistry (Fig. 4B). Two-way ANOVA revealed signiﬁcant stress
and drug effects (F(1,41) = 9.77, p=0.003 and F(2,41) = 4.20, p=0.02,
respectively; Fig. 5B). Post-hoc Fisher LSD test showed that CMS
signiﬁcantly reduced the number of BrdU-positive cells in both
untreated and vehicle treated animals (CTR vs. STR: p=0.03;
CTR-Veh vs. STR-Veh: p=0.01). Agomelatine reversed this stress-
induced effect (STR-Veh vs. STR-Ago: p=0.02), whereas it did not
inﬂuence the rate of cell survival in control animals (CTR-Veh vs.
CTR-Ago: p>0.05).
Effects of CMS and agomelatine on newly-born hippocampal
neuron maturation were assessed by DCX labeling (Fig. 4C). First,
we quantiﬁed the OD of DCX expression (Fig. 5C). Two-way ANOVA
revealed a signiﬁcant stress effect and a stress×drug interaction
(F(1,41) = 12.38, p=0.001 and F(2,41) = 11.41, p<0.001, respectively).
Post-hoc Fisher LSD test showed that both CMS and agomelatine
decreased the OD of DCX expression in the dentate gyrus (CTR vs.
STR:p=0.03;CTR-Vehvs. STR-Veh:p<0.001;CTR-Vehvs. CTR-Ago:
p<0.001). In stressed animals, agomelatine signiﬁcantly reversed
the decrease in DCX expression (STR-Veh vs. STR-Ago: p=0.04),
but did not restore it to the control level (CTR-Veh vs. STR-Ago:
p=0.004). Additionally,weanalyzed thepercentageof area covered
with DCX-positive cells (Fig. 5D). Two-way ANOVA revealed a sig-
niﬁcant stress×drug interaction (F(2,41) = 6.89, p=0.003). Post-hoc
Fisher LSD test showed that both CMS and agomelatine decreased
the percentage of dentate gyrus area covered with DCX-positive
cells (CTR vs. STR: p=0.008; CTR-Veh vs. STR-Veh: p=0.015;
CTR-Veh vs. CTR-Ago: p=0.002). Agomelatine increased DCX area
coverage in stressed animals, but this effect did not reach statistical
signiﬁcance (p>0.05).
4. Discussion
The present study investigated action of agomelatine in the rat
CMS model. Our data show that this stress paradigm differentially
affected distinct stages of the adult neurogenesis process. Whereas
CMS did not inﬂuence the rate of hippocampal cell proliferation, it
signiﬁcantly decreased the newborn cell survival and doublecortin
expression in the dentate gyrus. Notably, treatment with agomela-
tine completely normalized stress-affected cell survival and partly
reversed the reduced doublecortin expression. Altogether, these
data show that agomelatine has beneﬁcial effects on hippocampal
neurogenesis in the stress-compromised brain.Exposure to CMS led to a signiﬁcant decrease in body weight
gain. Similar effects on growth were previously reported in male
rats subjected to various chronic stress models [43,49,50]. In the
CMS model, reduction in growth may depend on a combination
of speciﬁc stressors, since both decrease [51–53] and no change




















































tig. 4. Representative photomicrographs of Ki-67 (A), BrdU (B) and DCX (C) immun
C) labeled cells.
n body weight [28,54] were found in this stress paradigm. In our
xperiment, the food deprivation stressor had obvious effects on
rowth; however, its induced weight loss was short-lasting and
ully recovered on the following day. Thus, the overall reduction in
rowth in the current CMS model cannot be attributed to a single
ooddeprivation stressor, but rather depends on a synergistic effect
f multiple stressors. The 3-week treatment with agomelatine also
ed to a signiﬁcant decrease in body weight gain, as observed in
ur previous study [35]. This reduction in growth is most likely
ediated through agomelatine’s action on melatonergic receptors,
smelatoninwas reported to decrease bodyweight in rodents [55].
n contrast to the growth reduction in rats, agomelatine treatment
oes not change body weight in humans [56,57].
Our results reveal that exposure to the CMS paradigm did not
hange the rate of hippocampal cell proliferation. Nevertheless,
t signiﬁcantly decreased the survival of hippocampal cells, born
efore the stress period. Furthermore, CMS was associated with
reduction in the expression of DCX, a protein present mainly
n the newborn immature neurons. It is interesting to note that
istinct aspects of the neurogenesis process might be differen-
ially inﬂuenced by stressful stimuli. Our data conﬁrm a previously
bserved discrepancy between stress effects on hippocampal cell
roliferation and survival in the CMS model [58]. A similar disso-
iation between different stages of neurogenesis was also found
n a related paradigm of chronic unpredictable stress [59]. These
esults suggest that the CMS paradigm inﬂuences a part, but not
he entire process of hippocampal neurogenesis. Such differen-
ial effects associated with CMS may hint to the role of this form
f stress in regulation of adult neurogenesis in the hippocam-
us. Sustained glucocorticoid exposure is considered as one of the
ediators of stress-induced changes in neurogenesis [24,60]. A
egree of the hypothalamic–pituitary–adrenal (HPA) axis activa-
ion in theCMSmodelvariesacrossdifferent studies.Whereas some
esearchers report mild to moderate increases in plasma corticos-
erone concentrations after exposure to CMS [52–54,61], others do
ot ﬁnd lasting changes in basal corticosterone levels [58,62], as
lso observed in our laboratory (unpublished results). The action of
orticosterone is mediated through two types of receptors, the glu-
ocorticoid receptor (GR) and the mineralocorticoid receptor (MR).
oth of these receptors are barely found on hippocampal progen-
tors, but their expression increases dynamically while newborn
ells progress through different stages of the neurogenesis process
o develop into mature neurons [63,64]. Altogether, this points to
limited role of corticosteroids in regulating adult neurogenesis
n the CMS model. Furthermore, these observations suggest that a
ariable sensitivity of the newborn cells to changes in the local glu-
ocorticoid environment might inﬂuence stress effects on different
spects of the neurogenesis process [65,66]. As mentioned above,
roliferating cells have low GR and MR levels that may contribute
o the lackof CMSeffects on the rate of cell proliferation. In contrast,
he survival of older hippocampal cells, expressing higher GR andings in the hippocampal dentate gyrus. Arrows point at Ki-67 (A), BrdU (B) and DCX
MR levels, may be more severely inﬂuenced by stress. In addition,
many other factors, including various proteins, neurotransmitters
and hormones, are suggested to regulate the proliferation and sur-
vival of newborn cells, and have differential effects on these two
processes [67,68]. Growth factors, especially, vascular endothelial
growth factor (VEGF) and BDNF, seem to play a crucial role in regu-
lating survival and differentiation of newly generated cells [69,70].
In line with this notion, reduced neurotrophin expression has been
repeatedly reported in the CMS model [28,29,61,71]. In sum, adult
hippocampal neurogenesis, and cell proliferation in particular, is a
highly dynamic process [43,72]. Hence, the future research should
consider the temporal dynamics of the stress response and time-
dependent effects of various stress mediators when designing new
studies of this kind [73,74].
Importantly, agomelatine treatment completely reversed the
CMS-induced decrease in hippocampal cell survival. This ﬁnding
conﬁrms the previous observations on actions of agomelatine in
the stress-compromised brain [35,75] as well as in a transgenic
animal model of depression [19]. Moreover, our data show that
this antidepressant partly reversed stress-induced reduction in
the DCX labeling in the dentate gyrus. Agomelatine treatment in
stressed animals signiﬁcantly increased the OD of DCX expres-
sion; however, its effects on the second measure of this analysis,
the area covered with DCX-positive cells, did not reach statis-
tical signiﬁcance. Such discrepancy might indicate that distinct
dimensions measured by two methods differ in their magnitude.
The OD reveals the intensity of the staining, and thus, reﬂects
the amount of expressed protein. Previously, we showed that
changes in the OD of DCX labeling correlate with alterations in the
number of immature DCX-positive neurons [43]. We also acknowl-
edged the differential inﬂuence of neurogenic regulators, such as
stress and antidepressants, on DCX-positive cells [35]. Earlier stud-
ies demonstrated that DCX protein is expressed dynamically by
heterogeneous cell populations, ranging fromproliferating progen-
itors to immature yet post-mitotic neurons [76–78]. A possibility
that stress and antidepressant treatment differentially regulate the
distinct populations of DCX cells was also conﬁrmed in the CMS
model [32]. According to the proposed hypothesis, chronic stress
might preferentially affect DCX-expressing post-mitotic neurons,
whereas antidepressant drugs might promote the proliferating
DCX-positive progenitors and accelerate their progression towards
mature neurons [32,79–81]. Our DCX data show that CMS reduced
both the amount of this protein as well as the relative number of
cell bodies and dendrites that express it. It is feasible that stress
downregulates the expression of DCX by decreasing the number of
immature neurons. On the other hand, agomelatine also reduced
both of these measures. Previous studies revealed that this antide-
pressant speeds up maturation of newborn neurons [21], resulting
in lower number of DCX-positive cells [20], and thereby, reduced
expression of DCX protein [35]. Interestingly, the present data
show that agomelatine signiﬁcantly, albeit partly, counteracted the
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Fig. 5. Effects of CMS and agomelatine treatment on adult hippocampal neuro-
genesis. Neither CMS nor agomelatine inﬂuenced hippocampal cell proliferation









reversed this stress effect (B). Both CMS and agomelatine treatment reduced OD
f the DCX expression in the dentate gyrus, whereas a combination of stress and
rug treatment partly rescued this effect (C). Accordingly, both CMS and agomela-
ine decreased the percentage of dentate gyrus area covered with the DCX-positive
eurons (D). *p<0.05, **p<0.01, ***p<0.001.tress-induced decrease in DCX reactivity but did not signiﬁcantly
hange the relative number of cells that express this protein. The
ffect of agomelatine on stress-altered DCX immunoreactivity was
ather mild. Therefore, it might have not manifested as asigniﬁcantesearch 218 (2011) 121–128
change in the measurement of area of coverage, associated with
higher individual variation.
Notably, our data show that agomelatine treatment did not
inﬂuencehippocampal cell proliferation or survival in non-stressed
rats. These ﬁndings are in line with our previous observations [35],
but contrast from earlier reports [20,21]. Discrepant effects among
studiesmay be due to subtle changes in the experimental protocols
as discussed in more detail previously [35].
The neurobiological effects achieved in the CMS model granted
valuable information on the action of agomelatine in the stress-
compromised brain. Strikingly, however, CMS did not induce
anhedonia as measured by preference for 1% sucrose solution over
water. In fact, rats showed a very high preference for sucrose
which did not diminish during a 5-week stress period. Both con-
trol and stressed animals drank an excessive amount of sweetened
solution as compared to their daily water intake. Such elevated
sucrose consumption indicates that rats liked/wanted it highly.
Notably, different neural systems underlie the conditions of liking
and wanting of pleasurable stimuli, suggesting a possible dissoci-
ation between these processes [82]. Although usually a brain likes
the rewards that it wants, yet, sometimes it may just want them
[83]. In view of this, the excess intake of sucrose solution may
indicate a strong wanting component of reward, not necessarily
accompanied by a liking element. The measurement of sucrose
consumption over water, thus, might not adequately reﬂect the
hedonic behavior. Consequently, data on sucrose intake and pref-
erence in the CMS studies should be interpreted with caution. In
some cases, for instance, the so called anhedonic state is a result
of increased sucrose consumption by control animals, without a
change in sucrose intake by their stressed counterparts [28]. Alto-
gether, there is a great deal of controversy in the methods used
for determination of anhedonia, and in their measured effects in
CMS studies. Despite numerous reports on stress-induced changes
in either sucrose preference or intake [10,27,29,33,51,54,61,84,85],
literature also reveals many contrasting results [71,86–90]. Such
controversy is suggested to stem from differences in experimental
designs and animal strains used; however, a solid explanation for
discrepant ﬁndings is still lacking [86,89,91].
Interestingly, our CMS paradigm induced changes in marble
burying behavior. Both the number of rats showing this behavior
as well as the number of their buried marbles was increased in the
groups subjected to CMS. The marble burying test is suggested to
measure anxiety-like and impulsive behavior, and is proposed to
detect potential antidepressant drugs; yet, the functional interpre-
tation of marble burying remains uncertain [92–94]. Nevertheless,
our ﬁndings reveal that exposure to CMS inﬂuenced the animals’
response to a novel object in the cage. Increased burying behavior
might indicate stress-heightened anxiety [95]. Although agomela-
tine had no statistically signiﬁcant effects in the marble burying
test, it did show a tendency to reduce the burying behavior. This
observation may reﬂect the anxiolytic action of agomelatine, pre-
viously demonstrated in various animal models [39,96], including
the marble burying test (unpublished results).
In summary, the present study used the CMS model in order
to elucidate effects of stress and agomelatine treatment on adult
hippocampal neurogenesis. Interestingly, this stress paradigm dif-
ferentially affected distinct aspects of the neurogenesis process:
whereas CMS did not alter the rate of cell proliferation, it decreased
the newborn cell survival and DCX expression in the dentate gyrus.
Importantly, treatment with agomelatine interfered with these
stress-associated changes in the brain. This antidepressant com-
pletely normalized stress-affected cell survival and partly reversed
reduced DCX expression. Taken together, these ﬁndings reveal
the ability of agomelatine to counteract stress-induced changes
in hippocampal neurogenesis, and conﬁrm its previously reported
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